Intensity Therapeutics shares rise 10.17% premarket after positive clinical data showing 50% fewer adverse events with INT230-6 at SABCS.

Intensity Therapeutics (INTS) surged 10.17% in premarket trading following the release of positive clinical trial data from its INVINCIBLE-4 study. The company reported a 50% reduction in grade 3 or higher adverse events in the INT230-6 cohort compared to standard of care (SOC) neoadjuvant chemotherapy, with favorable safety outcomes supporting its lead candidate for triple-negative breast cancer. Additionally, the announcement of a potential Phase 3 trial design omitting the toxic anthracycline doxorubicin ("the red devil") highlighted a path toward safer, more effective treatment regimens. These developments, coupled with presentations at the San Antonio Breast Cancer Symposium (SABCS), underscored progress toward accelerated regulatory approval via pathological complete response (pCR) as a surrogate endpoint. The news directly addressed investor concerns about treatment toxicity and efficacy in oncology, driving the sharp premarket rally.